H. Pylori Treatment in 2026: Choosing the Right Regimen Based on Local Resistance Patterns

Clinical Scenario: When the Textbook Algorithm Costs You Two Attempts

A 38-year-old woman from Hyderabad presents with a 6-month history of epigastric pain, confirmed duodenal ulcer on OGD, and a positive rapid urease test. She has no prior antibiotic exposure for H. pylori. Her treating physician prescribes standard PPI-clarithromycin-amoxicillin for 10 days. Post-treatment breath test at 6 weeks: positive. She is retreated with bismuth quadruple therapy (PPI-bismuth-tetracycline-metronidazole) for 14 days and successfully eradicates.

Both treatment attempts were avoidable as a sequence. Clarithromycin resistance in Hyderabad runs close to 100% in some institutional data - a figure that should make any gastroenterologist in that region default directly to bismuth quadruple therapy. The first course cost the patient ten additional days of unnecessary antibiotics, a failed test, and delayed ulcer healing. In a region with known high resistance, starting with bismuth quad is not aggressive escalation - it is correct first-line prescribing.

Which Regimen Goes First: A Decision Framework Mapped to Resistance Rates

The ACG 2024 Clinical Guideline makes only one strong recommendation: optimised bismuth quadruple therapy for 14 days as first-line treatment in treatment-naïve patients when antibiotic susceptibility is unknown. This consists of a PPI at standard dose twice daily, bismuth subcitrate 120–300 mg four times daily (tetracycline 500 mg four times daily - doxycycline is not a substitute) and metronidazole 500 mg three to four times daily.

For the Indian context, map your regimen choice to the resistance environment you practice in:

When clarithromycin resistance is unknown (most Indian centres) → Bismuth Quadruple Therapy (BQT) for 14 days. BQT employing at least 1,500 mg of metronidazole for 14 days remains effective despite high metronidazole resistance in India - a critical advantage given that metronidazole resistance alone does not reliably predict BQT failure in the same way it predicts triple-therapy failure.

When clarithromycin resistance is locally documented below 15% (rare in India; some northern centres) → Concomitant therapy (PPI-amoxicillin-clarithromycin-metronidazole, PAMC) for 14 days is an acceptable alternative. Its efficacy drops steeply once dual clarithromycin-metronidazole resistance is present.

Sequential therapy (PPI-amoxicillin ×5 days, then PPI-clarithromycin-metronidazole ×5 days) was an earlier workaround that has consistently failed to outperform BQT in high-resistance settings. It should not be prescribed as first-line in 2026.

After first-line failure → do not repeat the same regimen. If BQT was first-line, levofloxacin-based triple therapy is a reasonable second-line option where levofloxacin resistance remains low - but levofloxacin resistance now runs at 32.8% nationally, making culture-guided therapy the gold standard before any fluoroquinolone-based rescue.

A Frequently Overlooked Point: Metronidazole Resistance Does Not Doom Bismuth Quad

The single most common reason Indian gastroenterologists hesitate before prescribing BQT is the assumption that India's catastrophically high metronidazole resistance (77–78% in most series) will render bismuth quad ineffective. This reasoning is incorrect, and it matters enormously for practice. Bismuth quad's efficacy against metronidazole-resistant strains is preserved when the metronidazole dose is adequate (≥1,500 mg/day in divided doses) and the duration is 14 days. The pharmacokinetic explanation: high intraluminal bismuth concentrations and tetracycline's independent bactericidal activity compensate for metronidazole resistance in a way that no other combination achieves. The regimen you should worry about in a high-metronidazole-resistance setting is concomitant therapy - not bismuth quad. Swapping these two in your clinical reasoning is where eradication rates fall off a cliff.

Bottom Line for Clinical Practice

• Stop prescribing PPI-clarithromycin-amoxicillin triple therapy as empiric first-line in India. National clarithromycin resistance is 35–45%, and local data in South India, Gujarat, and Kashmir is worse. Eradication rates with triple therapy in these zones are below 70% - unacceptable for a treatable infection with a gastric cancer association.
  

• Default to optimised bismuth quadruple therapy for 14 days (PPI + bismuth subcitrate + tetracycline + metronidazole ≥1,500 mg/day) in all treatment-naïve patients where susceptibility is unknown. This is the ACG 2024 strong recommendation and directly applicable to the Indian resistance landscape.
  

• Do not substitute doxycycline for tetracycline. This is a well-documented prescribing error in India - doxycycline does not achieve equivalent intragastric concentrations and will reduce BQT efficacy.
  

• Sequential therapy is no longer a recommended first-line option in any setting where dual clarithromycin-metronidazole resistance is likely. Retire it from your practice.
  

• Test of cure is mandatory - urea breath test or stool antigen, at least 4 weeks post-treatment and 2 weeks off PPI. A negative endoscopy-only follow-up does not confirm eradication. This step is frequently skipped in Indian practice and perpetuates undetected treatment failure, ongoing transmission, and ulcer recurrence.
  

• For second-line and rescue therapy, consider culture-guided susceptibility testing if available in your centre, particularly before prescribing any levofloxacin-based regimen. Empiric fluoroquinolone rescue in a setting with 32% levofloxacin resistance is the same logical error as empiric clarithromycin first-line.

When you are standing in the endoscopy suite with a positive rapid urease test and need to make a prescribing decision in 90 seconds, GastroAGI can walk through the resistance context for your region, confirm the optimised BQT dosing, and flag the duration and test-of-cure timing - evidence-anchored, adapted to the Indian landscape.